1Flanc RS, Roberts MA, Strippoli GF, et al. Treatment of diffuse proliferative lupus nephritis : a meta-analysis of randomized controlled trials. Am J Kidney Dis,2004,43:197-208.
2Tan EM, Cohen AS, Fries JF, et al. The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum,1982,25 : 1271-1277.
3Bombardier C, Gladman DD, Urowitz MB, et al. Derivation of the SLEDAI. a disease activity index for lupus patients. Arthritis Rheum, 1992,35:630-640.
4Mok CC, Lau CS, Wong RW. Risk factors for ovarian failure in patients with systemic lupus erythmatosus receiving cyclophosphamide therapy. Arthritis Rheum, 1998,41:831-837.
5Mok CC, Wong RW, Lau CS. Ovarian failure and flares of systemic lupus erythematosus. Arthritis Rheum, 1999,42 : 1274-1280.
5Kaplan M , Merlob P, Regev R. Isreal guidelines for the manage- ment of neonatal hyperbilirubinemia and prevention of kemicterus [ J ]. J Perinatology,2008, 28 ( 2 ) : 389 - 397.
6AAP Subcommittee on Neonatal Hyperbilirubinemia. Neonatal Jaun- dice and Kemicterus [ J ]. Pediatrics, 2001,108 : 763 - 765.
7Maisels MJ . What' s in a Name? Physiologic and Pathologic Jaun- dice: The conundrum of defing normal bilirubin levels in the new- born [ J ]. Pediatrics ,2006,118 ( 2 ) : 805 - 807.
8Watchko JF. Identification of neonates at risk for hyperbilirubinemia : emerging clinical insights [ J ]. Pediatric Clin North Am, 2009,56: 671 - 687.
9Newman TB, Liljestrand P, Jeremy RI, et al. Outcomes among newbo- rns with total serum bilirubin level of 25mg per deciliter or more[ J]. N Engl J Med,2006,354: 1889 -1990.
